Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Ottawa

$27,000.00

Human pluripotent stem cell (hPSC)-derived liver sinusoidal endothelial cells (LSECs) to model hereditary hemorrhagic telangiectasia (HHT): A role for BMP9 in endothelial cell maturation

EF 2025-26

Résumé
Liver disease is a growing health burden in Canada. Although it encompasses conditions such as cancer, genetic disorders, and alcohol-related damage, many forms share a key feature, the loss-of-function of liver sinusoidal endothelial cells (LSECs). These cells filter blood through fenestrations, clear waste, and produce essential blood-clotting factors like Factor VIII. However, once removed from the liver, LSECs quickly lose their specialized traits, limiting research. To address this, our lab developed a stem cell-based system that generates fully functional human LSECs. Using this model, we study hereditary hemorrhagic telangiectasia (HHT), a vascular disorder affecting approximately 1 in 5,000 people globally. HHT causes artery-venous malformations that can lead to severe liver bleeding, often requiring transplantation. Liver involvement in HHT primarily stems from mutations in the ACVRL1 (HHT2) gene that encodes for ALK1, a core component of the BMP9 signalling pathway, though mutations in Endoglin (ENG; HHT1) also contribute. We hypothesize that the BMP9 pathway is essential for LSEC development and function. Therefore, my project employs CRISPR-Cas9 gene editing to disrupt HHT-related genes in human LSECs transplanted into immunocompromised mice. We will model HHT in two ways: first, by editing LSECs before transplantation to test if they can form properly, and secondly, by editing mature LSECs to see if they lose function. Ultimately, this work will uncover how BMP9 signalling governs LSEC biology and how its disruption leads to an HHT disease model. By understanding these mechanisms, we aim to identify new therapeutic strategies for HHT and other liver diseases, paving the way toward treatments that may one day reduce the need for liver transplants.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
572763
Name
Madahey Hakam
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Human pluripotent stem cell (hPSC)-derived liver sinusoidal endothelial cells (LSECs) to model hereditary hemorrhagic telangiectasia (HHT): A role for BMP9 in endothelial cell maturation
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Cell Transplantation; Crispr-Cas9 Editing; Disease Modelling; Hereditary Hemorrhagic Telangiectasia (Hht); Human Pluripotent Stem Cells (Hpscs); Humanized Mouse Model; Liver Sinusoidal Endothelial Cells (Lsecs); Stem Cell Therapy; Vascular Malformations; Venous Endothelial Cells (Vecs)
Abstract
Liver disease is a growing health burden in Canada. Although it encompasses conditions such as cancer, genetic disorders, and alcohol-related damage, many forms share a key feature, the loss-of-function of liver sinusoidal endothelial cells (LSECs). These cells filter blood through fenestrations, clear waste, and produce essential blood-clotting factors like Factor VIII. However, once removed from the liver, LSECs quickly lose their specialized traits, limiting research. To address this, our lab developed a stem cell-based system that generates fully functional human LSECs. Using this model, we study hereditary hemorrhagic telangiectasia (HHT), a vascular disorder affecting approximately 1 in 5,000 people globally. HHT causes artery-venous malformations that can lead to severe liver bleeding, often requiring transplantation. Liver involvement in HHT primarily stems from mutations in the ACVRL1 (HHT2) gene that encodes for ALK1, a core component of the BMP9 signalling pathway, though mutations in Endoglin (ENG; HHT1) also contribute. We hypothesize that the BMP9 pathway is essential for LSEC development and function. Therefore, my project employs CRISPR-Cas9 gene editing to disrupt HHT-related genes in human LSECs transplanted into immunocompromised mice. We will model HHT in two ways: first, by editing LSECs before transplantation to test if they can form properly, and secondly, by editing mature LSECs to see if they lose function. Ultimately, this work will uncover how BMP9 signalling governs LSEC biology and how its disruption leads to an HHT disease model. By understanding these mechanisms, we aim to identify new therapeutic strategies for HHT and other liver diseases, paving the way toward treatments that may one day reduce the need for liver transplants.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Madahey, Hakam
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~